Asymmetric dimethylarginine is not associated with subendocardial viability ratio in Rheumatoid Arthritis
Research output: Contribution to journal › Article › peer-review
Standard Standard
In: International Journal of Cardiology, Vol. 172, No. 1, 10.01.2014, p. 285-286.
Research output: Contribution to journal › Article › peer-review
HarvardHarvard
APA
CBE
MLA
VancouverVancouver
Author
RIS
TY - JOUR
T1 - Asymmetric dimethylarginine is not associated with subendocardial viability ratio in Rheumatoid Arthritis
AU - Sandoo, A.A.
AU - Kitas, G.
AU - Dimitroulas, T.
AU - Sandoo, A.
AU - Smith, J.P.
AU - Kitas, G.D.
PY - 2014/1/10
Y1 - 2014/1/10
N2 - Rheumatoid Arthritis (RA) is associated with increased cardiovascular (CV) mortality and reduced life expectancy predominantly due to increased rates of acute coronary syndromes including unrecognized myocardial infractions [1]. The increased CV burden in this population has prompted rheumatologists and cardiologists to a more early and vigilant screening for CV risk stratification even in asymptomatic patients. Asymmetric dimethylarginine (ADMA) and subendocardial viability ratio (SEVR) represent non-invasive methods of assessing endothelial dysfunction and coronary microvascular perfusion to subendocardium respectively, two pivotal players in the development of CV disease and myocardial ischemia
AB - Rheumatoid Arthritis (RA) is associated with increased cardiovascular (CV) mortality and reduced life expectancy predominantly due to increased rates of acute coronary syndromes including unrecognized myocardial infractions [1]. The increased CV burden in this population has prompted rheumatologists and cardiologists to a more early and vigilant screening for CV risk stratification even in asymptomatic patients. Asymmetric dimethylarginine (ADMA) and subendocardial viability ratio (SEVR) represent non-invasive methods of assessing endothelial dysfunction and coronary microvascular perfusion to subendocardium respectively, two pivotal players in the development of CV disease and myocardial ischemia
U2 - 10.1016/j.ijcard.2013.12.235
DO - 10.1016/j.ijcard.2013.12.235
M3 - Article
VL - 172
SP - 285
EP - 286
JO - International Journal of Cardiology
JF - International Journal of Cardiology
SN - 0167-5273
IS - 1
ER -